A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Midori NakagakiMichael BarrasCameron CurleyJason P ButlerGlen A KennedyPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2016)
Olanzapine was an effective treatment of breakthrough CINV. A single dose of palonosetron significantly reduced nausea up to 24 h.